A WORLD LEADER IN RIBOSOME TARGETED GENETIC THERAPIES

Familial Adenomatous
Polyposis (FAP) &
colorectal cancer (CRC)

FAP is caused by a mutation in the adenomatous polyposis coli (APC) gene coding for APC protein, which acts as a tumor suppressor and keeps cells from growing too fast or in an uncontrolled way.
It is characterized by polyps developing as early as the teens.1-3

Pipeline

Pipeline

Pipeline

Pipeline

80% OF CRC PATIENTS 80% OF CRC PATIENTS
have an APC mutation.

Our program to address FAP and APC mutant colon cancers includes TURBO-ZM™ based molecules ZKN-013 and ZKN-074.

  • 8-week study in APCMin mice planned to evaluate potential of RMAs to treat FAP

Existing data support clinical development

Erythromycin treatment
shown to reduce both
the amount and size
of polyp

Clinical Trial Success

Responder Analysis of Erythromycin Treatment

ZKN013

Preclinical Results

Erythromycin treatment
shown to reduce both
the amount and size
of polyps

Preclinical Results

Response to ZKN-013
shown in tumor grafts
ex-vivo from patients
with FAP derived CRC